IPO information (June 2021)
Physitrack listed on the Premier segment on Nasdaq First North on June 18, 2021. Qualified investors can find all information, including the prospectus on our IPO page.
Physitrack aims to achieve annual organic sales growth exceeding 30% in the medium term, further supplemented by impact from future add-on acquisitions.
Physitrack targets an EBITDA margin of 40-45% in the medium term, with potential short term margin contractions due to add-on acquisitions impacting margins.
Physitrack aims to reinvest profits and cash flows in organic growth initiatives and add-on acquisitions to support further value creation, and therefore, does not expect to pay dividends in the medium term.
Physitrack’s financial targets stated above constitute forward-looking information. The financial targets are based upon a number of estimates and assumptions relating to, among others, the development of Physitrack’s industry, business, result of operations and financial position, and are subject to risks and uncertainties.
Board of directors
About the Board of Directors
The company's board of directors consist of four directors including the chairperson, who are appointed for the period until the end of the next annual shareholders' meeting.
Subject to the UK Companies Act, the articles of association and to any directions given by special resolution of the company, the business of the company will be managed by the board of directors, which may exercise all the powers of the company, whether relating to the management of the business or not. The directors have a fiduciary duty owed to the company.
In summary, directors owe a duty to:
- Act within the powers conferred by the company's constitution;
- Promote the success of the company; and
- Exercise independent judgment, reasonable care, skill and diligence, avoid conflicts of interest, not accept benefits from third parties and declare interests in (proposed) transactions or arrangements.
Directors also owe a duty of confidentiality to the company, and the terms on which they are engaged by the company, especially in the case of executive directors, may impose or give rise to further duties and obligations.
Conflict of interest
In accordance with the articles of association, a director must declare to the directors any potential conflict of interest, so the directors can decide on how to address the conflict. The directors may decide to authorise matters presented by a director that would, if not authorised, involve a breach under the UK Companies Act. If authorised to act in conflict of interest, the director will be obliged to conduct him/herself in accordance with any terms and conditions imposed by the directors.
Appointment and removal of directors
Subject to the company's articles of association, the company may by ordinary resolution appoint a person who is willing to be a director. The board of directors also have the power at any time to appoint any person who is willing to act as a director.
In line with the UK Corporate Governance, at each annual general meeting every director shall retire from office and each retiring director may offer himself for re-appointment by the members. A director that is re-appointed will be treated as continuing in office without a break until the next annual general meeting where he shall again be eligible for re-election.
According to the articles of association, the board of directors may, but shall not be obliged to, establish before each annual general meeting an election committee consisting of the three largest shareholders on the date falling three months before the annual general meeting. The election committee may express in writing their preferences for the re-election or otherwise of directors at the relevant annual general meeting. In addition to any power of removal conferred by the UK Companies Act, the company may remove a director before the expiry of his period of office and appoint another person who is willing to act to be a director in his place.
FNCA Sweden AB, Nybrogatan 34
114 39 Stockholm
IR & Media contact
The purpose of Physitrack's Investor Relations is to continuously keep investors and the capital market informed about the company's operations and development. We welcome any questions or comments.
Henrik Molin, CEO